124 related articles for article (PubMed ID: 34684076)
1. Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients.
Aran V; Zalis M; Montella T; de Sousa CAM; Ferrari BL; Gil Ferreira C
Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684076
[No Abstract] [Full Text] [Related]
2. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Gibert J; Clavé S; Hardy-Werbin M; Taus Á; Rocha P; Longarón R; Piquer G; Chaib I; Carcereny E; Morán T; Salido M; Dalmases A; Bellosillo B; Arriola E
Lung Cancer; 2020 Feb; 140():42-45. PubMed ID: 31862576
[TBL] [Abstract][Full Text] [Related]
3. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
4. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
5. Comparison of real-life data from patients with NGS panel negative and
Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ
Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577
[TBL] [Abstract][Full Text] [Related]
6. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.
El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L
PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337
[TBL] [Abstract][Full Text] [Related]
7. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
8. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
10. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
12. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
[TBL] [Abstract][Full Text] [Related]
14. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
15. Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations.
Hu Y; Ren S; Chen C; Liang Q; Yu F; Liu W
Thorac Cancer; 2020 Jul; 11(7):2018-2022. PubMed ID: 32415761
[TBL] [Abstract][Full Text] [Related]
16. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
[TBL] [Abstract][Full Text] [Related]
17. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
[TBL] [Abstract][Full Text] [Related]
18. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
[TBL] [Abstract][Full Text] [Related]
19. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
20. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]